Get startedLog in
    Picture of Immix Biopharma logo

    IMMX — Immix Biopharma News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    All News

    Brief: Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

    Picture of Immix Biopharma logoImmix Biopharma
    23/05/2025 14:13
    May 23 (Reuters) - Immix Biopharma Inc IMMX.O:

IMMIX BIOPHARMA FURTHER EXPANDS U.S. CLINICAL SITES FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS TRIAL NEXICART-2

IMMIX BIOPHARMA INC: ANTICIPATE COMPLETING NEXICART-2 CLINICAL TRIAL AHEAD OF SCHEDULE

Source text: ID:nGNE40Mzkz

Further company coverage: IMMX.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Immix Biopharma

    See all news